Quantcast

Latest AEZS-108 Stories

2011-07-07 06:30:00

QUÓ°BEC CITY, July 7, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company")  today announced that an abstract on its anticancer compound, AEZS-108, has been accepted and will be presented during a poster session at the upcoming European Society of Medical Oncology Congress to be held September 23-27, 2011, at the Stockholm International Fairs in Stockholm, Sweden. AEZS-108, a targeted cytotoxic peptide conjugate, is...

2010-11-18 05:15:00

Encouraging trend observed in overall survival with limited side-effects QUEBEC, Nov. 17 /PRNewswire/ - Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ) (the "Company"), earlier today, presented Phase 2 positive efficacy and safety data for its compound, AEZS-108, in advanced endometrial cancer. The trial was conducted by the German AGO Study Group and centers in Bulgaria. The presentation was made by Prof. Gunter Emons, Chairman, Department of Obstetrics & Gynaecology...

2010-11-10 06:30:00

QUEBEC CITY, Nov. 10 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") today announced that it will present a poster on Phase 2 results for AEZS-108 in advanced endometrial cancer at the 22(nd) EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held at the Berlin Estrel Hotel and Convention Centre in Berlin, GermanyNovember 16 through 19, 2010. Abstract #378:   "Phase 2 study of AEZS-108 (AN-152), a targeted...

2010-08-05 06:30:00

Grant awarded to Dr. Jacek Pinski to conduct the study at the Norris Comprehensive Cancer Center of the University of Southern California QUEBEC CITY, Aug. 5 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the National Institutes of Health ("NIH") has awarded Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer...

2010-06-28 06:30:00

Collaboration is part of Aeterna Zentaris' strategy of personalized approach to treatment with AEZS 108, the Company's LHRH receptor targeted conjugate with doxorubicin, being investigated in multiple cancers QUEBEC CITY, June 28 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced a collaborative study with Almac's Diagnostics division for the Company's...

2010-06-07 06:30:00

Encouraging trend observed in overall survival QUEBEC CITY, June 7 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it presented positive efficacy and safety data for its doxorubicin targeted conjugate compound, AEZS-108, in ovarian cancer. The presentation was made by Prof. Gunter Emons, Chairman, Department of Obstetrics & Gynaecology...

2010-05-06 06:30:00

QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in...

2009-11-02 06:00:00

Preliminary evaluation after completion of treatment phase shows that primary efficacy endpoint has been met for patients with advanced-stage platinum-resistant, taxane-pretreated ovarian cancer. QUEBEC CITY, Nov. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related